Cleveland Clinic research findings suggest that effective steroidal antiandrogens share common metabolic activities and metabolites should be closely examined for effects on tumor survival.
New evidence shows that men on active surveillance of prostate cancer can safely wait at least five years between surveillance biopsies. Study authors hope new findings increase appeal of disease monitoring and reduce patient and provider anxiety.
A Cleveland Clinic research team finds that tumors in a single prostate can be very diverse, leading to the question: Is sampling the largest, most established or accessible tumor is the best approach?
Newly approved treatment for prostate cancer helps men keep the gland and maintain sexual/biological function, while delivering same outcomes as radiation therapy with less treatment burden.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Genomic assessment of 3+3=6 prostate tumors shows up to 20 percent of these low-grade cancers harbor molecular characteristics of aggressive disease. Using these tests could help aid patient selection for active surveillance.
In choosing among treatment options available to men diagnosed with prostate cancer, urologists and patients should consider optimal urinary, bowel and sexual function as goals of care, in addition to disease-free survival. This study provide some guidance.
While the rate of RUF resolution is high, patients should be carefully counseled about the possibility of needing permanent diversion and carefully selected for optimal surgical management.
Cleveland Clinic physician-researcher recognized as a Top Ten Clinical Research Achievement awardee by national organization of senior researchers and thought leaders from leading academic health centers.
New study shows weaknesses in Gleason scoring system, offers more nuanced classifications that could simultaneously reduce overtreatment and more accurately identify men with high-risk disease.
While patients with high-risk prostate cancer should receive prompt treatment, data suggest that patients and urologists need not rush others into treatment.